IO Biotech is developing T-win, a therapeutic cancer-vaccine technology designed to recruit naturally occurring T cells to disrupt multiple immunosuppressive processes in the tumor microenvironment. The lead candidate is in advanced clinical development for melanoma with plans to expand to other solid tumor indications.
